Background A recombinant adenovirus type-5 vector-based vaccine expressing the glycoprotein of Ebola Zaire Makona variant showed good safety and immunogenicity in a phase 1 trial of healthy Chinese adults. We aimed to assess the safety and immunogenicity of this vaccine in healthy adults in Sierra Leone and to determine the optimal dose.
Introduction
Ebola virus disease results in mortality as high as 90% in infected human beings and up to 100% in non-human primates, and has become a severe threat to public health worldwide. 1 The 2014 epidemic in west Africa associated with Zaire ebolavirus is the largest outbreak of Ebola virus disease in history, causing around 28 600 cases and 11 298 deaths until October, 2015. 2 Unlike previous outbreaks, this epidemic predominantly occurred in urban areas, affecting both community members and healthcare workers. 3, 4 As an emergency response to this epidemic, various vector-based Ebola vaccine candidates have been developed and tested in clinical trials. Several candidate vaccines have shown promising results, [5] [6] [7] [8] and a recombinant vesicular stomatitis virus-based vaccine expressing the glycoprotein of Zaire ebolavirus (rVSV-ZEBOV) showed high effi cacy in an interim analysis of a phase 3 trial in Guinea. 9 However, more evidence on the safety and effi cacy of rVSV-ZEBOV is still needed before its use can be approved.
In a preclinical study, 10 signifi cant protection against Ebola virus challenge was observed in non-human primates immunised with an adenovirus type-5 vectorbased Ebola vaccine, suggesting that this vaccine has potential to be used in human beings. In a phase 1 trial, 11 a recombinant adenovirus type-5 vector-based Ebola vaccine expressing the glycoprotein of the Ebola Zaire Makona variant showed good safety and immunogenicity in healthy Chinese adults after one dose. Thus, we aimed to further investigate the safety and immunogenicity of this vaccine in a larger population from Sierra Leone, which was severely affl icted by the 2014 Ebola virus disease epidemic, and to determine the optimal dose of this vaccine. 12 
Methods

Study design and participants
In this single-centre, randomised, double-blind, placebocontrolled, phase 2 clinical trial at Sierra Leone-China Friendship Hospital, Freetown, Sierra Leone, we recruited healthy participants aged 18-50 years. Participants were eligible if they were HIV negative (confi rmed by blood test at enrolment), had no history of Ebola virus infection, and had no previous immunisation with other Ebola vaccine candidates (see appendix for full inclusion and exclusion criteria).
This trial was reviewed and approved by the Sierra Leone Ethics and Scientifi c Review committee and Pharmacy Board of Sierra Leone. We did the study in accordance with the Declaration of Helsinki and Good Clinical Practice. All participants provided written informed consent at least 1 day before eligibility screening. The study protocol is available online.
Randomisation and masking
Participants were sequentially enrolled and randomly assigned (2:1:1) to receive high-dose vaccine (1·6 × 10¹¹ viral particles), low-dose vaccine (8·0 × 10¹⁰ viral particles), or placebo. Block randomisation (block size of eight) was based on a computer-generated block randomisation list generated with SAS version 9.3 by an independent statistician who had no involvement in the rest of the trial. The vaccines and placebo had identical packaging and were labelled with a randomised code as the unique identifi er for each participant. Participants, investigators, and study staff were masked from treatment allocation during the study, except for two study pharmacists who prepared and delivered the study vaccines in ready-to-use syringes to the investigator. The pharmacists had no involvement in any other study procedures and were not allowed to reveal treatment allocation. Staff undertaking laboratory analyses were masked from treatment allocation throughout the study.
Procedures
The study vaccine was developed by Beijing Institute of Biotechnology (Beijing, China) and Tianjin CanSino Biotechnology (Tianjin, China), and contained replication-defective adenovirus type-5 vectors expressing the glycoprotein of Ebola Zaire Makona variant (GenBank number KJ660346). The placebo contained the vaccine excipients only, with no viral particles. We administered double injections of vaccines containing 8·0 × 10¹⁰ viral particles per dose to participants in the high-dose group (ie, total dose 1·6 × 10¹¹ viral particles) and double injections of vaccines containing 4·0 × 10¹⁰ viral particles per dose to participants in the low-dose group (ie, total dose 8·0 × 10¹⁰ viral particles), with one injection in each arm. Participants in the control group received two injections of placebo, with one injection in each arm. We observed participants for immediate adverse reactions for 60 min after vaccination and followed them up for solicited injection-site or systemic adverse reactions
Research in context
Evidence before this study We searched PubMed for clinical trial reports and ClinicalTrials.gov for unpublished randomised trials, using the search terms "Ebola" or "Ebolavirus" and "vaccine", with no language restrictions, up to Aug 17, 2016 
Added value of this study
In this phase 2 trial, we investigated the safety and immunogenicity of this vaccine in healthy Sierra Leonean adults at 8·0 × 10¹⁰ viral particles or 1·6 × 10¹¹ viral particles, and followed up participants for 6 months after injection. This is the fi rst report of this vaccine administered to populations in Ebola-endemic regions (ie, west Africa). Vaccine recipients had high humoral immune responses of glycoprotein-specific antibodies that peaked at day 28 and decreased signifi cantly by about 85% 6 months after injection. Participants receiving 8·0 × 10¹⁰ or 1·6 × 10¹¹ viral particles showed no diff erence in post-vaccination antibody responses.
Implications of all the available evidence
The adenovirus type-5 vector-based Ebola virus vaccine is safe and immunogenic in Sierra Leonean adults, and the optimal dose is 8·0 × 10¹⁰ viral particles. However, the short duration of antibody responses raised the need for prime-boost immunisation.
See Online for appendix For the trial protocol see http:// www.jshealth.com/jgzn/zzjg/ ymlcpjs/ymlcpjs_gzdt/201612/ W020161214426550507006. pdf occurring within 7 days of vaccination and unsolicited adverse events or medication use within 28 days of vaccination. Serious adverse events were recorded throughout the 6 month follow-up period. HIV tests were done at the end of follow-up for any HIV infection acquired during the study period. Blood samples were collected from participants immediately before vaccination and at follow-up visits (days 14, 28, and 168 after injection). We assessed Ebolaspecifi c antibody responses against the vaccine-matched glycoprotein with ELISA, reported as 90% eff ective concentration (EC 90 ; the concentration at which there is a 90% decrease in antigen binding), with a subtraction of the pre-vaccination optical density. 13 ELISA EC 90 was measured at each timepoint, and optical density was read at 450 nm. A positive antibody response was defi ned as an ELISA EC 90 value of at least 10. For ELISA EC 90 values of less than 10, a value of 5 was used for geometric mean titre calculation. Neutralising antibody titres against human adenovirus type-5 vector were measured with the serum neutralisation assay.
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Outcomes
The primary safety outcome was occurrence of solicited adverse reactions (both injection-site and systemic adverse reactions) within 7 days of vaccination. The primary immunogenicity outcome was glycoproteinspecifi c antibody responses, measured before vaccination and at days 14, 28, and 168 after vaccination.
Secondary safety outcomes were unsolicited adverse events within 28 days of vaccination, serious adverse events during the 6 month follow-up period, and HIV infection rate during follow-up. Severity of adverse events was graded according to the standard guidelines issued by the China Food and Drug Administration. 15 The secondary immunogenicity outcome was titres of neutralising antibodies against human adenovirus type-5 vector.
Statistical analysis
We calculated sample size on the basis of results from a previous phase 1 study, 11 using PASS software (version 11.0). Assuming that 95% of participants respond in the low-dose group, 99·9% respond in the high-dose group, and 5% respond in the placebo group, we used a 2:1:1 randomisation ratio to ensure 80% power at α=0·05 to show a 10% diff erence between the low-dose and highdose groups. We needed at least 207 participants in the high-dose group and 104 each in the low-dose and placebo groups. Assuming a 15% loss to follow-up, we aimed to recruit 500 participants (250 in high-dose group, 125 in low-dose group, and 125 in placebo group). Such a sample size would also produce reliable data for frequent adverse events in each group.
The safety analysis was done by intention to treat, and the primary immunogenicity outcome was analysed in the full-analysis cohort-ie, all participants who were given the vaccine and had blood samples drawn for antibody tests after vaccination. Because immunity to adenovirus type-5 vectors varies among populations and could aff ect vaccine responses, 14 we did a subgroup analysis of safety and immunogenicity, stratifi ed by baseline adenovirus type-5 neutralising antibody titres (low [ Antibody responses were reported as geometric mean titre with 95% CIs. We used χ² test or Fisher's exact test for categorical data, ANOVA for log-transformed antibody titres, and Wilcoxon rank-sum test for nonnormal data. Statistical tests were done with a two-sided α of 0·05 and analysed by an independent statistician using SAS (version 9.3).
An independent data safety monitoring board (consisting of two public health physicians, one clinician, one epidemiologist, one immunologist, and one biostatistician) was established before the start of the trial to oversee the study process and determine the causal relation between serious adverse events and the vaccine. This trial is registered with the Pan African Clinical Trials Registry, number PACTR201509001259869.
Role of the funding source
The funders of the study were involved in protocol design but had no role in data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Between Oct 10 and Oct 28, 2015, we recruited and screened 618 healthy adults for eligibility, of whom 500 were randomly assigned to receive high-dose vaccine (n=250), low-dose vaccine (n=125), or placebo (n=125; fi gure 1). Baseline characteristics were largely similar across the treatment groups (table 1). All participants completed the solicited safety observation period of 7 days. Blood samples were drawn from 496 (99%) participants at day 14, 497 (99%) at day 28, and 493 (99%) at day 168.
132 (53%) of 250 participants in the high-dose group, 60 (48%) of 125 in the low-dose group, and 54 (43%) of 125 in the placebo group reported at least one solicited adverse reaction within 7 days of vaccination (table 2) . Most adverse reactions were mild and self-limiting, arising during the first 24 h after injection and lasting less than 48 h. However, in a post-hoc analysis, the occurrence of solicited injection-site adverse reactions diff ered significantly among the three groups (p=0·0169). In multiple comparisons based on an adjusted α of 0·017, the diff erence between the highdose and low-dose groups was not signifi cant (p=0·9002), whereas both high-dose and low-dose groups had signifi cantly more solicited injection-site adverse reactions than the placebo group (p=0·0077 for high dose vs placebo and p=0·0361 for low dose vs placebo). The most frequent solicited injection-site adverse reaction was pain, and the most common systemic adverse reactions were headache and fever (table 2). 147 (59%) participants in the high-dose group, 81 (65%) participants in the low-dose group, and 67 (54%) participants in the placebo group reported at least one or more unsolicited adverse reactions within 28 days of vaccination. No particular safety issues associated with pre-existing adenovirus type-5 vector neutralising antibodies were noted (appendix pp 3-5).
During the 6 month follow-up period, one fatal acute asthma episode was reported in a woman aged 44 years who received the high-dose vaccine. She had had an asthma diagnosis for more than 5 years but did not disclose her asthma history at enrolment, since she had not had any asthma attacks for years and had been inhaler free. 5 days after the injection, she reported a moderate cough and diffi cult breathing to a study investigator, but her symptoms were relieved quickly after taking medications. She felt much better and even participated in an evening church service later that day. However, she had a severe asthma attack around midnight and was declared dead on arrival at the hospital. The data safety monitoring board reviewed all information of this serious adverse event and concluded that it was unrelated to the vaccine before being unmasked from treatment allocation of this participant. Additionally, two participants in the high-dose group reported serious adverse events-one had malaria 4 months after the injection and one had gastroenteritis 5 months after the injection. Both events were considered unrelated to the vaccine and resolved after hospital admission.
Although all participants included in the study had negative HIV screening results at enrolment, six participants (fi ve in the high-dose group and one in the placebo group) were identifi ed as HIV positive at day 168. The occurrences of HIV infection during the follow-up period did not diff er signifi cantly among treatment groups (p=0·3223).
Glycoprotein-specifi c antibody response was detected from day 14 onwards, with at least 96% of responders in both high-dose and low-dose groups at day 14 (table 3) . However, the proportion of responders did not diff er signifi cantly between the low-dose and high-dose groups at all three timepoints. Glycoprotein-specifi c antibody response peaked at day 28, with a geometric mean titre of 1471·8 (95% CI 1151·0-1881·8) in the low-dose group and 2043·1 (1762·4-2368·4) in the high-dose group, whereas geometric mean titres in the placebo group remained around 6·0-6·8 throughout the follow-up period (table 3) . We noted a transiently higher geometric mean titre in the high-dose group than in the low-dose group at day 28 (p=0·0495), but the diff erences were not signifi cant at other timepoints (p=0·0671 on day 14 and p=1·000 on day 168). Both the low-dose vaccine and the high-dose vaccine induced strong antibody responses (geometric mean titres >1000) within 28 days of vaccination, irrespective of pre-existing adenovirus type-5 neutralising antibody titres (fi gure 2). However, the vaccine-elicited antibody responses decreased signifi cantly after the peak: geometric mean titre at day 168 was 223·3 (148·2-336·4) in the low-dose group and 254·2 (185·0-349·5) in the high-dose group. Similar results were also found in the per-protocol cohort (appendix p 6).
Before vaccination, most participants had pre-existing neutralising antibodies against adenovirus type 5, and geometric mean titres were well balanced across the treatment groups at baseline (table 1). Geometric mean titres of these neutralising antibodies increased by more than 10 times in both low-dose and high-dose groups at day 14 (appendix p 7). Although the titres dropped quickly since then, recipients of the low-dose and high-dose vaccines still had antibody titres at day 168 that were 3-5 times higher than that at baseline. 
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Discussion
The recombinant adenovirus type-5 vector-based Ebola vaccine was fi rst tested in a phase 1 trial 11 of healthy Chinese adults and had an acceptable safety profi le. At a dose of 1·6 × 10¹¹ viral particles, the vaccine was highly immunogenic regardless of the presence of pre-existing immunity against the vaccine vector, whereas the immunogenicity of the low-dose vaccine (4·0 × 10¹⁰ viral particles) was signifi cantly weakened by pre-existing immunity and the negative eff ects of pre-existing antibodies against the vaccine vector could not be overcome. On the basis of this fi nding, we increased the dose from 4·0 × 10¹⁰ viral particles to 8·0 × 10¹⁰ viral particles in the low-dose vaccine in this phase 2 trial, and compared it with the high-dose vaccine (1·6 × 10¹¹ viral particles) to further study the safety and immunogenicity of this vaccine in healthy Sierra Leonean adults.
In this phase 2 trial, the high-dose vaccine was associated with increased injection-site reactions, which was consistent with fi ndings of the phase 1 study. 11 However, no severe safety concern of the vaccine was raised, and most adverse reactions were mild or moderate. One participant in the high-dose group had a fatal serious adverse event (asthma episode) 5 days after vaccination. This participant did not report her previous asthma history at enrolment and was therefore randomised and vaccinated. Although this episode was considered unlikely to have been triggered by the vaccine, this individual should not have been included in the study in the fi rst place. We regret that we were unable to identify her history of asthma before she received vaccination.
Results from a preclinical challenge study 10 with nonhuman primates immunised with adenovirus type-5 vector-based Ebola vaccine showed that a titre of 1000 or higher had 77% protection against death. In our study, one shot of the vaccine could elicit strong glycoproteinspecifi c antibody responses (geometric mean titre >1000) in both low-dose and high-dose groups. Even in participants with pre-existing immunity to the vector, the low-dose vaccine (8·0 × 10¹⁰ viral particles) still elicited a humoral response similar to that of the highdose vaccine (1·6 × 10¹¹ viral particles). Thus, the optimal dose was identifi ed as 8·0 × 10¹⁰ viral particles. However, durability of the vaccine-elicited specifi c antibodies was insuffi cient in the following months, with a much lower antibody titre on day 168 than that observed in Chinese participants who received 1·6 × 10¹¹ viral particles in the phase 1 trial (unpublished data). This fi nding is consistent with other reports of rVSV-ZEBOV vaccine trials in Africa and Europe, 6 suggesting that, in populations from Ebola-endemic regions, protective antibodies are considerably less durable than those in populations from non-endemic regions. This issue deserves in-depth attention, since the populations most in need seem more diffi cult to protect.
As mentioned in previous reports, 16, 17 a concern about the adenovirus type-5 vector is that the activated vectorspecific CD4-positive T cells could increase HIV-1 acquisition in vaccine recipients with positive antiadenovirus type-5 immunity. We did HIV tests at enrolment to exclude HIV-infected individuals from the study. At the end of the study (day 168), fi ve participants in the high-dose group and one in the placebo group were identifi ed as HIV positive, corresponding to annual infection rates of 4% and 1·6 %, respectively. Although HIV infection rates did not diff er signifi cantly among the treatment groups, this result is still important to note. Since this fi nding could be potentially confounded by false-negative results of participants who were in the early phase of HIV infection at enrolment and 6 months might not be long enough to identify diff erences in infection risk, an extended follow-up period for new HIV infection is needed to further address this issue.
A limitation of our study was that the adenovirus type-5 vector vaccine platform could be compromised by pre-existing immunity against the vector, since a large proportion of adults worldwide have such immunity. 18, 19 For example, more than 85% of healthy Sierra Leonean adults in our study had pre-existing immunity against this vector. We tried to circumvent this problem by increasing the vaccine dose administered. However, our results showed that although a high titre of glycoprotein-specifi c antibodies could be achieved within 28 days of vaccination at a dose of 8·0 × 10¹⁰ viral particles or more, humoral immunity was not as robust and long-lasting as we expected. Another limitation was that we did not measure T-cell immune responses elicited by the vaccine because we did not have suffi cient laboratory equipment. Although we recruited a relatively large population from an Ebola-endemic region, this singlecentre trial might limit generalisability of the results.
Taking vaccine profi les, manufacturing costs, and production capacity into consideration, 8·0 × 10¹⁰ viral particles seem to be an optimal dose, since it could induce a high level of glycoprotein-specifi c antibody responses and confer substantial protection to vaccinated individuals, at least in the short term. Thus, the adenovirus type-5 vector-based Ebola vaccine at a dose of 8·0 × 10¹⁰ viral particles should be investigated in phase 3 trials. However, the short durability of vaccine-elicited antibodies indicates a need for a prime-booster regimen to prolong immunity in future studies. Besides the immunogenicity of this vaccine, its effi cacy against Ebola virus disease in epidemic areas still needs to be investigated. Since there is no identifi able high-risk population that can be targeted without the presence of an Ebola epidemic and Ebola outbreaks are unpredictable and sporadic, vaccine effi cacy trials after the 2014 epidemic will be very diffi cult to conduct.
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